73 related articles for article (PubMed ID: 29138382)
1. [A Case of Retroperitoneal Abscess Due to Acute Appendicitis during Neo-Adjuvant Chemotherapy for Breast Cancer].
Oba T; Maeno K; Ito K; Ishizone S; Hanaoka T
Gan To Kagaku Ryoho; 2017 Nov; 44(11):1029-1032. PubMed ID: 29138382
[TBL] [Abstract][Full Text] [Related]
2. [A case of acute appendicitis which occurred during chemotherapy for breast cancer].
Oshida S; Hayashi K; Habiro T; Hatate K; Sengoku N
Gan To Kagaku Ryoho; 2013 Nov; 40(12):2417-9. PubMed ID: 24394131
[TBL] [Abstract][Full Text] [Related]
3. A multicenter prospective phase II trial of neoadjuvant epirubicin, cyclophosphamide, and 5-fluorouracil (FEC100) followed by cisplatin-docetaxel with or without trastuzumab in locally advanced breast cancer.
A L-Tweigeri T; AlSayed A; Alawadi S; Ibrahim M; Ashour W; Jaafar H; Abulkhair O; A L-Abdulkarim H; Khalid H; Ajarim D;
Cancer Chemother Pharmacol; 2016 Jan; 77(1):147-53. PubMed ID: 26563257
[TBL] [Abstract][Full Text] [Related]
4. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial.
Joensuu H; Bono P; Kataja V; Alanko T; Kokko R; Asola R; Utriainen T; Turpeenniemi-Hujanen T; Jyrkkiö S; Möykkynen K; Helle L; Ingalsuo S; Pajunen M; Huusko M; Salminen T; Auvinen P; Leinonen H; Leinonen M; Isola J; Kellokumpu-Lehtinen PL
J Clin Oncol; 2009 Dec; 27(34):5685-92. PubMed ID: 19884557
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.
Gianni L; Pienkowski T; Im YH; Roman L; Tseng LM; Liu MC; Lluch A; Staroslawska E; de la Haba-Rodriguez J; Im SA; Pedrini JL; Poirier B; Morandi P; Semiglazov V; Srimuninnimit V; Bianchi G; Szado T; Ratnayake J; Ross G; Valagussa P
Lancet Oncol; 2012 Jan; 13(1):25-32. PubMed ID: 22153890
[TBL] [Abstract][Full Text] [Related]
6. Impact of genetic variability and treatment-related factors on outcome in early breast cancer patients receiving (neo-) adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide, and docetaxel.
Vulsteke C; Pfeil AM; Schwenkglenks M; Pettengell R; Szucs TD; Lambrechts D; Peeters M; van Dam P; Dieudonné AS; Hatse S; Neven P; Paridaens R; Wildiers H
Breast Cancer Res Treat; 2014 Oct; 147(3):557-70. PubMed ID: 25168315
[TBL] [Abstract][Full Text] [Related]
7. The combination of epirubicin plus docetaxel as neoadjuvant chemotherapy in locally-advanced breast cancer.
Hirano A; Shimizu T; Imamura H; Watanabe O; Kinoshita J; Okabe T; Kimura K; Kamimura M; Domoto K; Aiba M; Ogawa K
Anticancer Res; 2006; 26(1B):581-4. PubMed ID: 16739324
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant Sequential Docetaxel Followed by High-Dose Epirubicin in Combination With Cyclophosphamide Administered Concurrently With Trastuzumab. The DECT Trial.
Pizzuti L; Barba M; Giannarelli D; Sergi D; Botti C; Marchetti P; Anzà M; Maugeri-Saccà M; Natoli C; Di Filippo S; Catenaro T; Tomao F; Amodio A; Carpano S; Perracchio L; Mottolese M; Di Lauro L; Sanguineti G; Di Benedetto A; Giordano A; Vici P
J Cell Physiol; 2016 Nov; 231(11):2541-7. PubMed ID: 27187274
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study.
Untch M; Rezai M; Loibl S; Fasching PA; Huober J; Tesch H; Bauerfeind I; Hilfrich J; Eidtmann H; Gerber B; Hanusch C; Kühn T; du Bois A; Blohmer JU; Thomssen C; Dan Costa S; Jackisch C; Kaufmann M; Mehta K; von Minckwitz G
J Clin Oncol; 2010 Apr; 28(12):2024-31. PubMed ID: 20308670
[TBL] [Abstract][Full Text] [Related]
10. Retroperitoneal abscess resulting from perforated acute appendicitis: analysis of its management and outcome.
Hsieh CH; Wang YC; Yang HR; Chung PK; Jeng LB; Chen RJ
Surg Today; 2007; 37(9):762-7. PubMed ID: 17713730
[TBL] [Abstract][Full Text] [Related]
11. Retroperitoneal abscess resulting from perforated retrocecal appendicitis:a case report.
Ofrim OI; Legrand MJ
Acta Chir Belg; 2013; 113(2):149-51. PubMed ID: 23741936
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of liposome-encapsulated doxorubicin plus cyclophosphamide, followed by sequential trastuzumab plus docetaxel as primary systemic therapy for breast cancer patients with HER2 overexpression or amplification.
Saracchini S; Foltran L; Tuccia F; Bassini A; Sulfaro S; Micheli E; Del Conte A; Bertola M; Gion M; Lorenzon M; Tumolo S
Breast; 2013 Dec; 22(6):1101-7. PubMed ID: 24074879
[TBL] [Abstract][Full Text] [Related]
13. ER, PgR, Ki67, p27(Kip1), and histological grade as predictors of pathological complete response in patients with HER2-positive breast cancer receiving neoadjuvant chemotherapy using taxanes followed by fluorouracil, epirubicin, and cyclophosphamide concomitant with trastuzumab.
Kurozumi S; Inoue K; Takei H; Matsumoto H; Kurosumi M; Horiguchi J; Takeyoshi I; Oyama T
BMC Cancer; 2015 Sep; 15():622. PubMed ID: 26345461
[TBL] [Abstract][Full Text] [Related]
14. Docetaxel, cyclophosphamide, and trastuzumab as neoadjuvant chemotherapy for HER2-positive primary breast cancer.
Nakatsukasa K; Koyama H; Oouchi Y; Imanishi S; Mizuta N; Sakaguchi K; Fujita Y; Imai A; Okamoto A; Hamaoka A; Soushi M; Fujiwara I; Kotani T; Matsuda T; Fukuda K; Morita M; Kawakami S; Kadotani Y; Konishi E; Yanagisawa A; Goto M; Yamada K; Taguchi T
Breast Cancer; 2017 Jan; 24(1):92-97. PubMed ID: 26874836
[TBL] [Abstract][Full Text] [Related]
15. A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients.
Pierga JY; Delaloge S; Espié M; Brain E; Sigal-Zafrani B; Mathieu MC; Bertheau P; Guinebretière JM; Spielmann M; Savignoni A; Marty M
Breast Cancer Res Treat; 2010 Jul; 122(2):429-37. PubMed ID: 20480225
[TBL] [Abstract][Full Text] [Related]
16. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial.
Roché H; Fumoleau P; Spielmann M; Canon JL; Delozier T; Serin D; Symann M; Kerbrat P; Soulié P; Eichler F; Viens P; Monnier A; Vindevoghel A; Campone M; Goudier MJ; Bonneterre J; Ferrero JM; Martin AL; Genève J; Asselain B
J Clin Oncol; 2006 Dec; 24(36):5664-71. PubMed ID: 17116941
[TBL] [Abstract][Full Text] [Related]
17. Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer.
Iwata H; Sato N; Masuda N; Nakamura S; Yamamoto N; Kuroi K; Kurosumi M; Tsuda H; Akiyama F; Ohashi Y; Toi M
Jpn J Clin Oncol; 2011 Jul; 41(7):867-75. PubMed ID: 21719750
[TBL] [Abstract][Full Text] [Related]
18. [Clinical evaluation of effects from neo-adjuvant chemotherapy with epirubicin plus paclitaxel in cases of locally advanced breast cancer].
Tong F; Zhou B; Yang D; Cao Y; Liu P; Liu H; Qiao X; Zhang J
Gan To Kagaku Ryoho; 2002 Jul; 29(7):1147-52. PubMed ID: 12145994
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of neoadjuvant docetaxel, vinorelbine, and trastuzumab followed by surgery and adjuvant doxorubicin plus cyclophosphamide in women with human epidermal growth factor receptor 2-overexpressing locally advanced breast cancer.
Limentani SA; Brufsky AM; Erban JK; Jahanzeb M; Lewis D
J Clin Oncol; 2007 Apr; 25(10):1232-8. PubMed ID: 17296975
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of neoadjuvant chemotherapy with docetaxel followed by epirubicin in stage II/III breast cancer.
Ramaswamy B; Povoski SP; Rhoades C; Allen J; Hauger M; Young D; Burak W; Farrar W; Yee L; Kendra K; Somasundaram S; Orlowski RZ; Shapiro CL
Breast Cancer Res Treat; 2005 Sep; 93(1):67-74. PubMed ID: 16184461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]